Entrada Therapeutics
TRDA
52 hedge funds and large institutions have $361M invested in Entrada Therapeutics in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 6 reducing their positions, and 4 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 6
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
11% more funds holding
Funds holding: 47 → 52 (+5)
8% more capital invested
Capital invested by funds: $334M → $361M (+$26.9M)
3.45% less ownership
Funds ownership: 78.69% → 75.24% (-3.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.1M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.13M |
| 3 |
Jane Street
New York
|
+$793K |
| 4 |
CA
CHI Advisors
New York
|
+$753K |
| 5 |
HF
HRT Financial
New York
|
+$513K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$4.74M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$407K |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$300K |
| 4 |
E
Ergoteles
New York
|
-$190K |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$164K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Osaic Holdings
Scottsdale,
Arizona
| $4.35K | – | – | – |
|
52
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $2.9K | +$2.67K | +200 | New |
|
53
Wells Fargo
San Francisco,
California
| $2.45K | +$13 | +1 | +0.6% |
|
|
E
54
Ergoteles
New York
| – | -$190K | -14,019 | Closed |
|
|
55
Balyasny Asset Management
Chicago,
Illinois
| – | -$164K | -12,132 | Closed |
|
56
State of Wisconsin Investment Board
Madison,
Wisconsin
| – | -$148K | -10,971 | Closed |
|
TRDA Hedge Fund Activity: Q1 2023 in Review
52 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q1 2023, worth a combined $361M — up 8% from $334M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TRDA positions and 4 closed out — a net gain of 5 holders — while 24 added to existing stakes and 6 trimmed.
The largest buyer was Millennium Management, adding an estimated $2.1M. The largest seller was Goldman Sachs, cutting an estimated $4.74M.
- 52 institutional investors held Entrada Therapeutics (TRDA) as of Q1 2023, up from 47 in Q4 2022.
- Funds reported $361M of Entrada Therapeutics stock for Q1 2023, up 8% quarter-over-quarter.
- 9 funds opened new Entrada Therapeutics positions in Q1 2023 and 4 closed out, a net change of +5 holders.
- The largest Entrada Therapeutics buyer in Q1 2023 was Millennium Management, an estimated $2.1M added.
- The largest Entrada Therapeutics seller in Q1 2023 was Goldman Sachs, an estimated $4.74M sold.
Based on aggregated 13F filings for Q1 2023.